TEST:

Decipher Bladder Test

The strong association of ERS-late scores with both pathological response and EFS suggests this signature could guide patient stratification and treatment selection. These findings support future trials combining immunotherapy with anti-estrogens, in both neoadjuvant and advanced urothelial carcinoma settings.

"Veracyte...announced that multiple abstracts will be presented at the 40th Annual European Association of Urology Congress (EAU25) demonstrating the clinical performance and utility of its Decipher tests in prostate and bladder cancer. Additionally, independent performance data supporting the company’s minimal residual disease (MRD) testing platform for muscle-invasive bladder cancer will be unveiled from a large, multicenter trial. The EAU25 meeting is taking place March 21-24 at IFEMA Madrid in Spain."

"Veracyte, Inc...today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility of its Decipher Prostate and Decipher Bladder tests to help guide treatment for patients with prostate and bladder cancer."

Luminal tumors represent less aggressive disease, reflected by lower rates of pathological upstaging and favorable OS with RC compared with nonluminal tumors. Molecular subtyping suggests that in clinically non-muscle-invasive bladder cancer, luminal tumors harbor less aggressive disease, as reflected by lower rates of pathological upstaging to muscle-invasive disease and favorable outcomes with radical cystectomy, in comparison with nonluminal bladder cancer.

"Veracyte, Inc...today announced new data that reinforce the ability of its Decipher Bladder Genomic Subtyping Classifier to help improve staging for patients with bladder cancer, based on their tumors’ molecular subtype. The findings, published in European Urology Open Science, show that the test can help clinicians better determine which patients are more likely to harbor more aggressive disease than suggested by their initial clinical staging following transurethral resection of bladder tumor (TURBT)."

This study validates the performance of the GC for identifying UCs with a luminal favourable subtype, harbouring less aggressive tumour biology.

For the remaining three patients, all were treated with platinum-based chemotherapy for eventual metastatic disease but all three showed progressive disease with limited overall survival, highlighting their aggressive course. The non-luminal subtype and lack of FGFR alteration may partly explain the poor overall outcomes while the real-world benefit of next generation sequencing for clinical use in UTUC patients require further clarification in a larger cohort study.

P=N/A; N=165 --> 2 | Trial completion date: Feb 2027 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Feb 2025 --> May 2024; Low enrollment

"Veracyte...announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches. They also show that the research-use-only Decipher GRID (Genomic Resource for Intelligent Discovery) tool is helping to advance scientific understanding of these diseases. The findings were presented during the conference taking place May 3-6 in San Antonio."

"Veracyte, Inc...today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2024, the annual meeting of the American Urological Association, taking place May 3-6 in San Antonio. Studies to be presented include those that evaluate the clinical utility of the company’s Decipher tests in guiding treatment decisions for patients with prostate or bladder cancer. Other presentations will explore new insights into these cancers’ underlying biology, which researchers derived through use of Veracyte’s whole-transcriptome-based Decipher GRID research tool."

Molecular subtyping suggests that luminal tumors harbor a less aggressive disease state reflected by lower rates of upstaging compared to non-luminal tumors. Critically, luminal tumors in the cT2 population showed a significantly improved outcomes compared to non-luminal tumors, even in the absence of systemic chemotherapy.

Application of a lncRNA-based classifier to two cystectomy cohorts revealed that FGFR3+ patients with cT1 disease have excellent outcomes after RC, suggesting these less aggressive tumors are both organ-confined and readily cured with surgery alone. These findings represent a first step towards identifying cT1 patients with less favorable biology that may warrant systemic treatment before radical surgery.